Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Sep;47(9):2574-2576.
doi: 10.1038/s41440-024-01802-8. Epub 2024 Jul 11.

Will esaxerenone be added to the antihypertensive treatment strategy of practicing physicians as a second-line antihypertensive drug?

Tetsuro Yoshida  1
Affiliations
Comment

Will esaxerenone be added to the antihypertensive treatment strategy of practicing physicians as a second-line antihypertensive drug?

Tetsuro Yoshida. Hypertens Res. 2024 Sep.
No abstract available

Keywords: Esaxerenone; Mineralocorticoid receptor antagonists; Trichlormethiazide.

PubMed Disclaimer

Comment on

References

    1. Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S. Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study). Hypertension. 2020;75:51–8. - DOI - PubMed
    1. Kario K, Ohbayashi H, Hashimot M, Itabashi N, Kato M, Uchiyama K, et al. Home blood pressure-lowering effect of a non-steroidal mineralocorticoid receptor blocker, esaxerenone, versus thichlormethiazide for uncontrolled hypertension: the EXCITE-HT randomized controlled study. Hypertens Res. https://doi.org/10.1038/s41440-024-01762-z .
    1. Kario K, Wang JG, Chia YC, Wang TD, Li Y, Siddique S, et al. The HOPE Asia network 2022 up-date consensus statement on morning hypertension management. J Clin Hypertens. 2022;24:1112–20. - DOI
    1. Kario K, Nishizawa M, Kato M, Ishii H, Uchiyama K, Nagai M, et al. Nighttime home blood pressure lowering effect of esaxerenone in patients with uncontrolled nocturnal hypertension: the EARLY-NH study. Hypertens Res. 2023;46:1782–94. - DOI - PubMed - PMC
    1. Yamamoto E, Usuku H, Sueta D, Suzuki S, Nakamura T, Matsui K, et al. Efficacy and Safety of Esaxerenone in Hypertensive Patients with Left Ventricular Hypertrophy (ESES-LVH) Study: a multicenter, open-label, prospective, interventional study. Adv Ther. 2024;41:1284–303. - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources